Bavarian Nordic A/S/€BAVA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.
Ticker
€BAVA
Sector
Primary listing
XGAT
Employees
1,667
Headquarters
Hellerup, Denmark
Website
BAVA Metrics
BasicAdvanced
€2.4B
12.70
€2.41
1.08
-
Price and volume
Market cap
€2.4B
Beta
1.08
52-week high
€32.50
52-week low
€16.50
Average daily volume
5.3K
Financial strength
Current ratio
3.345
Quick ratio
1.584
Long term debt to equity
0.78
Total debt to equity
1.129
Interest coverage (TTM)
313.23%
Profitability
EBITDA (TTM)
287.749
Gross margin (TTM)
53.10%
Net profit margin (TTM)
22.04%
Operating margin (TTM)
24.03%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
€518,340
Management effectiveness
Return on assets (TTM)
6.88%
Return on equity (TTM)
12.65%
Valuation
Price to earnings (TTM)
12.702
Price to revenue (TTM)
2.788
Price to book
1.48
Price to tangible book (TTM)
3.02
Price to free cash flow (TTM)
-41.503
Free cash flow yield (TTM)
-2.41%
Free cash flow per share (TTM)
-0.737
Growth
Revenue change (TTM)
6.13%
Earnings per share change (TTM)
98.24%
3-year revenue growth (CAGR)
51.69%
10-year revenue growth (CAGR)
16.60%
3-year earnings per share growth (CAGR)
20.66%
10-year earnings per share growth (CAGR)
10.32%
Bulls say / Bears say
The U.S. FDA’s approval of the freeze-dried formulation of Jynneos enhances logistical flexibility and shelf-life, likely strengthening Bavarian Nordic’s supply agreements and easing global stockpiling (Reuters).
The U.S. CDC’s formal adoption of advisory panel recommendations for chikungunya vaccines in May 2025, including Bavarian Nordic’s candidate, could accelerate U.S. uptake and reimbursement coverage (Reuters).
Bavarian Nordic delivered Q2 2025 revenue of 1.65 billion crowns, surpassing expectations and prompting an upward revision of full-year guidance to 6.0–6.6 billion crowns, reflecting robust demand across its travel health and public preparedness segments (Reuters).
Ongoing discussions with private equity firms Nordic Capital and Permira on a potential takeover inject strategic uncertainty, risking distraction from core R&D and commercialization activities (Reuters).
With Danish pension fund ATP (10% stake) publicly declining to support the 233-crown takeover offer, the proposed bid may fail, potentially capping shareholder value absent alternative proposals (Reuters).
Revenue from Jynneos relies heavily on government contracts like those with BARDA, exposing Bavarian Nordic to policy shifts and budgetary constraints that could materially impact future orders (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bavarian Nordic A/S stock?
Bavarian Nordic A/S (BAVA) has a market cap of €2.4B as of October 08, 2025.
What is the P/E ratio for Bavarian Nordic A/S stock?
The price to earnings (P/E) ratio for Bavarian Nordic A/S (BAVA) stock is 12.7 as of October 08, 2025.
Does Bavarian Nordic A/S stock pay dividends?
No, Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Bavarian Nordic A/S dividend payment date?
Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Bavarian Nordic A/S?
Bavarian Nordic A/S (BAVA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.